Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. CHYM
3. BRZE
4. USO
5. QCOM
6. DYN
7. PHVS
8. NOVN:SW
9. USB
10. NVS

Go back to Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) Delayed: 57.67 --0 (-0%)
Previous Close $57.67    52 Week High $17.00 
Open $57.67    52 Week Low $3.55 
Day High $57.67    P/E N/A 
Day Low $57.67    EPS $-1.33 
Volume 15,197